


BioMab, Inc. discovers and develops cutting edge immune-based diagnostics and therapeutics to enable healthcare professionals to provide patients with personalized care.

The company was founded through close collaboration with a leading research group specializing in the field of antibody technologies and targeted therapy at Academia Sinica, Taiwan.




## The expansion method of NK cells via DSNK media cultured (without protein coating).


- No feeder cells required, no need to purify NK cells prior to expansion
- NK cell amplifying fold > 3,000 folds
- Purity of NK > 90 %

Easy to operate

Highly purity



## Cytotoxicity effect tests



## Clinical Grade Purification and Expansion of Natural Killer Cells

	NK cell therapy release specification	Company X	Company Y	BioMab DSNK
CD56 <sup>+</sup> CD3 <sup>-</sup> (%)	>50%	>90%	40~70%	>90%
Viability(7-AAD)	>70%	>70%	>80%	>70%
Cytotoxicity to K562 at 20:1 of E:T	>20%	>40% at 1:1 of E:T	20~40% at 20:1 of E:T	>40% at 10:1 of E:T
(%CD56 <sup>+</sup> CD3 <sup>-</sup> )NKG2D <sup>+</sup>	n/a	>96%	++	>90%
(%CD56 <sup>+</sup> CD3 <sup>-</sup> )NKp30 <sup>+</sup>	n/a	>94%	+++	>90%
(%CD56 <sup>+</sup> CD3 <sup>-</sup> )NKp44 <sup>+</sup>	n/a	~40%	+	dim

Critical Reviews™ in Oncogenesis, 19(1-2):121-132 (2014)

For more information, please contact us at

[joshua.ho@biomabinc.com](mailto:joshua.ho@biomabinc.com)

<http://www.biomabinc.com>

